Drug Addiction - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 108 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Drug Addiction - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Drug Addiction - Pipeline Review, H2 2014', provides an overview of the Drug Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Drug Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Drug Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Drug Addiction Overview 10
Therapeutics Development 11
Pipeline Products for Drug Addiction - Overview 11
Pipeline Products for Drug Addiction - Comparative Analysis 12
Drug Addiction - Therapeutics under Development by Companies 13
Drug Addiction - Therapeutics under Investigation by Universities/Institutes 15
Drug Addiction - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Drug Addiction - Products under Development by Companies 19
Drug Addiction - Products under Investigation by Universities/Institutes 20
Drug Addiction - Companies Involved in Therapeutics Development 21
Gilead Sciences, Inc. 21
Aphios Corporation 22
Teva Pharmaceutical Industries Limited 23
Addex Therapeutics Ltd 24
Biotie Therapies Corp. 25
Camurus AB 26
Curemark, LLC 27
Rottapharm SpA 28
Omeros Corporation 29
Immunovaccine, Inc. 30
Kyorin Pharmaceutical Co., Ltd. 31
D&A Pharma SAS 32
Embera NeuroTherapeutics, Inc. 33
Lightlake Therapeutics Inc. 34
SK Biopharmaceuticals Co., Ltd. 35
LondonPharma Ltd 36
Drug Addiction - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
nepicastat hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ibudilast - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
buprenorphine hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TV-1380 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
cannabidiol - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(oxazepam + metyrapone) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SKL-N05 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
LT-22 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ASB - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
methadone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GS-6673 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
dronabinol - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ADX-88178 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ADX-71441 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
OMS-527 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Vaccine for Cocaine Addiction - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Vaccine for Cocaine Addiction - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MH-6 Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Vaccine for Drug Addiction - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Ibogaine Analog - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecules to Inhibit DAT for Cocaine Addiction and Cocaine Abuse - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CM-1212 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
methoxycoronaridine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules to Inhibit BRD for Cancer and Cocaine Dependence - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CR-5542 Series - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecule to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Drug for Dependence - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Drug Addiction - Recent Pipeline Updates 85
Drug Addiction - Dormant Projects 96
Drug Addiction - Discontinued Products 97
Drug Addiction - Product Development Milestones 98
Featured News & Press Releases 98
May 27, 2014: Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014 98
Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction 98
Jun 18, 2013: MediciNova Announces Presentation Of Preliminary Results From Phase Ib Study Of MN-166 In Methamphetamine Addiction At 75th Annual Meeting Of CPDD 98
May 10, 2013: Biotie Starts Phase II Clinical Study With Nepicastat In Cocaine Dependence 99
May 06, 2013: Scripps Scientists Report Preclinical Study Results Of Heroin Vaccine 100
Feb 25, 2013: MediciNova's MN-166 Receives Fast Track Designation From FDA For Treatment Of Methamphetamine Dependence 101
Feb 12, 2013: Collegium Pharma Announces Notice Of Allowance For US Patent Covering Oxycodone DETERx Extended-release Opioid Product 103
Jan 03, 2013: MediciNova Provides Development Update On MN-166 103
Nov 08, 2012: Catalyst Pharma Announces Top-Line Results Of CPP-109 Phase IIb Trial For Cocaine Addiction 104
Nov 01, 2012: Scripps Research Announces Promising Results In Early Tests Of Meth Vaccine 104
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 108
Disclaimer 108

List of Tables
Number of Products under Development for Drug Addiction, H2 2014 11
Number of Products under Development for Drug Addiction - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Drug Addiction - Pipeline by Gilead Sciences, Inc., H2 2014 21
Drug Addiction - Pipeline by Aphios Corporation, H2 2014 22
Drug Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 23
Drug Addiction - Pipeline by Addex Therapeutics Ltd, H2 2014 24
Drug Addiction - Pipeline by Biotie Therapies Corp., H2 2014 25
Drug Addiction - Pipeline by Camurus AB, H2 2014 26
Drug Addiction - Pipeline by Curemark, LLC, H2 2014 27
Drug Addiction - Pipeline by Rottapharm SpA, H2 2014 28
Drug Addiction - Pipeline by Omeros Corporation, H2 2014 29
Drug Addiction - Pipeline by Immunovaccine, Inc., H2 2014 30
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 31
Drug Addiction - Pipeline by D&A Pharma SAS, H2 2014 32
Drug Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2014 33
Drug Addiction - Pipeline by Lightlake Therapeutics Inc., H2 2014 34
Drug Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 35
Drug Addiction - Pipeline by LondonPharma Ltd, H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Assessment by Combination Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 44
Number of Products by Stage and Route of Administration, H2 2014 46
Number of Products by Stage and Molecule Type, H2 2014 48
Drug Addiction Therapeutics - Recent Pipeline Updates, H2 2014 85
Drug Addiction - Dormant Projects, H2 2014 96
Drug Addiction - Discontinued Products, H2 2014 97